CFM
BIO icon

Catalyst Funds Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Catalyst Funds Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,300
Closed -$1.21M – 356
2025
Q3 		$1.21M Buy
4,300
+1,725
+67% +$469K 0.18% 123
2025
Q2 		$621K Buy
2,575
+875
+51% +$207K 0.17% 164
2025
Q1 		$414K Sell
1,700
-3,000
-64% -$902K 0.11% 215
2024
Q4 		$1.54M Hold
4,700
– – 0.38% 55
2024
Q3 		$1.57M Buy
+4,700
New +$1.49M 0.35% 52

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Catalyst Funds Management's BIO Position: Q4 2025 in Review

Catalyst Funds Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 4,300 shares — an estimated $1.21M sold.

Catalyst Funds Management first reported a position in BIO in Q3 2024 and held it in 5 quarters. The position peaked at $1.57M in Q3 2024. 399 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Catalyst Funds Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 4,300 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $1.21M.
  • Catalyst Funds Management first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and held it in 5 quarters.
  • Catalyst Funds Management's Bio-Rad Laboratories Class A position peaked at $1.57M in Q3 2024.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Catalyst Funds Management's 13F filing for Q4 2025, filed 9 Feb 2026.